PMID- 36263028
OWN - NLM
STAT- MEDLINE
DCOM- 20221021
LR  - 20221024
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Simultaneous genotyping for human platelet antigen systems and HLA-A and HLA-B 
      loci by targeted next-generation sequencing.
PG  - 945994
LID - 10.3389/fimmu.2022.945994 [doi]
LID - 945994
AB  - In order to treat the alloimmunization platelet transfusion refractoriness (PTR), 
      human leukocyte antigen (HLA)-type and/or human platelet antigen (HPA)-type 
      matched platelets between donors and patients are usually used. Therefore, 
      genotyping of HLA-A and HLA-B loci, as well as HPA systems, for donors and 
      patients, is of great significance. However, there is a rare report of genotyping 
      for HLA-A and HLA-B loci as well as HPA systems at the same time. In this study, 
      a high-throughput method for simultaneous genotyping of HLA-A and HLA-B loci, as 
      well as HPA genotyping, was developed. A RNA capture probe panel was designed 
      covering all exon sequences of the GP1BA, GP1BB, ITGA2, CD109, ITGB3, and ITGA2B 
      genes and HLA-A and HLA-B loci. The HLA-A, HLA-B, and 34 HPA systems were 
      genotyped using a targeted next-generation sequencing (NGS) method. The genotypes 
      of the HLA-A and HLA-B loci, as well as the HPA, were assigned based on the 
      nucleotides in the polymorphism sites. Using the NGS method, 204 unrelated blood 
      specimens were successfully genotyped for all 34 HPA systems as well as HLA-A and 
      HLA-B loci. The accuracy of the NGS method was 100%. Only HPA-2, HPA-3, HPA-5, 
      HPA-6w, HPA-15, and HPA-21w showed polymorphism with frequencies of 0.9412, 
      0.6863, 0.9853, 0.9779, 0.4314, and 0.9951 for a allele, respectively. Thirty-two 
      single nucleotide variants (SNVs) were detected. Of them, 12 SNVs can lead to 
      amino acid change. HLA-A*11:01 and HLA-B*46:01 are the most common alleles for 
      HLA-A and HLA-B loci. A targeted next-generation sequencing method for 
      simultaneously genotyping HPA systems and HLA-A and HLA-B loci was first 
      established, which could be used to create a database of HLA-typed and/or 
      HPA-typed unrelated donors.
CI  - Copyright (c) 2022 Wang, You, He, Hong, He, Tao and Zhu.
FAU - Wang, Jielin
AU  - Wang J
AD  - Human Leukocyte Antigen Typing Laboratory, Blood Center of Zhejiang Province, 
      Hangzhou, China.
AD  - Human Leukocyte Antigen Typing Laboratory, Key Laboratory of Blood Safety 
      Research, Hangzhou, China.
FAU - You, Xuan
AU  - You X
AD  - Human Leukocyte Antigen Typing Laboratory, Blood Center of Zhejiang Province, 
      Hangzhou, China.
AD  - Human Leukocyte Antigen Typing Laboratory, Key Laboratory of Blood Safety 
      Research, Hangzhou, China.
FAU - He, Yanmin
AU  - He Y
AD  - Human Leukocyte Antigen Typing Laboratory, Blood Center of Zhejiang Province, 
      Hangzhou, China.
AD  - Human Leukocyte Antigen Typing Laboratory, Key Laboratory of Blood Safety 
      Research, Hangzhou, China.
FAU - Hong, Xiaozhen
AU  - Hong X
AD  - Human Leukocyte Antigen Typing Laboratory, Blood Center of Zhejiang Province, 
      Hangzhou, China.
AD  - Human Leukocyte Antigen Typing Laboratory, Key Laboratory of Blood Safety 
      Research, Hangzhou, China.
FAU - He, Ji
AU  - He J
AD  - Human Leukocyte Antigen Typing Laboratory, Blood Center of Zhejiang Province, 
      Hangzhou, China.
AD  - Human Leukocyte Antigen Typing Laboratory, Key Laboratory of Blood Safety 
      Research, Hangzhou, China.
FAU - Tao, Sudan
AU  - Tao S
AD  - Human Leukocyte Antigen Typing Laboratory, Blood Center of Zhejiang Province, 
      Hangzhou, China.
AD  - Human Leukocyte Antigen Typing Laboratory, Key Laboratory of Blood Safety 
      Research, Hangzhou, China.
FAU - Zhu, Faming
AU  - Zhu F
AD  - Human Leukocyte Antigen Typing Laboratory, Blood Center of Zhejiang Province, 
      Hangzhou, China.
AD  - Human Leukocyte Antigen Typing Laboratory, Key Laboratory of Blood Safety 
      Research, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220929
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antigens, Human Platelet)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 0 (Nucleotides)
RN  - 0 (Amino Acids)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Humans
MH  - *Antigens, Human Platelet/genetics
MH  - Genotype
MH  - HLA-A Antigens/genetics
MH  - High-Throughput Nucleotide Sequencing
MH  - HLA-B Antigens/genetics
MH  - Nucleotides
MH  - Amino Acids/genetics
MH  - RNA
PMC - PMC9575554
OTO - NOTNLM
OT  - human leukocyte antigen
OT  - human platelet antigens
OT  - next-generation sequencing
OT  - platelet blood donors
OT  - platelet transfusion refractoriness
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/21 06:00
MHDA- 2022/10/22 06:00
PMCR- 2022/01/01
CRDT- 2022/10/20 02:52
PHST- 2022/05/17 00:00 [received]
PHST- 2022/08/30 00:00 [accepted]
PHST- 2022/10/20 02:52 [entrez]
PHST- 2022/10/21 06:00 [pubmed]
PHST- 2022/10/22 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.945994 [doi]
PST - epublish
SO  - Front Immunol. 2022 Sep 29;13:945994. doi: 10.3389/fimmu.2022.945994. eCollection 
      2022.